UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 27

Sortiert nach

Low bone toughness in the TallyHO model of juvenile type 2 diabetes does not worsen with age

Bone (New York, N.Y.), 2018-05, Vol.110, p.204-214

2018

Volltextzugriff (PDF)

Postnatal loss of the insulin receptor in osteoprogenitor cells does not impart a metabolic phenotype

Scientific reports, 2020-06, Vol.10 (1), p.8842-8842, Article 8842

2020

Volltextzugriff (PDF)

SGLT2 inhibitor therapy improves blood glucose but does not prevent diabetic bone disease in diabetic DBA/2J male mice

Bone (New York, N.Y.), 2016-01, Vol.82, p.101-107

2016

Volltextzugriff (PDF)

The impact of SGLT2 inhibitors, compared with insulin, on diabetic bone disease in a mouse model of type 1 diabetes

Bone (New York, N.Y.), 2017-01, Vol.94, p.141-151

2017

Volltextzugriff (PDF)

Is insulin an anabolic agent in bone? Dissecting the diabetic bone for clues

American journal of physiology: endocrinology and metabolism, 2005-11, Vol.289 (5), p.E735-E745

2005

Volltextzugriff (PDF)

Matrix metalloproteinases: their potential role in the pathogenesis of diabetic nephropathy

Endocrine, 2009-02, Vol.35 (1), p.1-10

2009

Volltextzugriff (PDF)

Microalbuminuria in Type 1 Diabetes Is Associated With Enhanced Excretion of the Endocytic Multiligand Receptors Megalin and Cubilin

Diabetes care, 2009-07, Vol.32 (7), p.1266-1268

2009

Volltextzugriff (PDF)

Increasing duration of type 1 diabetes perturbs the strength–structure relationship and increases brittleness of bone

Bone (New York, N.Y.), 2011-04, Vol.48 (4), p.733-740

2011

Volltextzugriff (PDF)

Insulin-like growth factor binding protein proteolysis

Trends in endocrinology and metabolism, 2003-05, Vol.14 (4), p.176-181

2003

Volltextzugriff (PDF)

Pharmacologic Inhibition of Myostatin With a Myostatin Antibody Improves the Skeletal Muscle and Bone Phenotype of Male Insulin‐Deficient Diabetic Mice

JBMR plus, 2023-11, Vol.7 (11), p.e10833-n/a

2023

Volltextzugriff (PDF)

Runt-Related Transcription Factor 2 (RUNX2) and RUNX2-Related Osteogenic Genes Are Down-Regulated throughout Osteogenesis in Type 1 Diabetes Mellitus

Endocrinology (Philadelphia), 2008-04, Vol.149 (4), p.1697-1704

2008

Volltextzugriff (PDF)

RASopathies: The musculoskeletal consequences and their etiology and pathogenesis

Bone (New York, N.Y.), 2021-11, Vol.152, p.116060-116060, Article 116060

2021

Volltextzugriff (PDF)

Osteo-promoting effects of insulin-like growth factor I (IGF-I) in a mouse model of type 1 diabetes

Bone (New York, N.Y.), 2013-11, Vol.57 (1), p.36-40

2013

Volltextzugriff (PDF)

Preserving and restoring bone with continuous insulin infusion therapy in a mouse model of type 1 diabetes

Bone Reports, 2017-12, Vol.7 (C), p.1-8

2017

Volltextzugriff (PDF)

Loss of Insulin Receptor in Osteoprogenitor Cells Impairs Structural Strength of Bone

Journal of Diabetes Research, 2014-01, Vol.2014, p.703589-9

2014

Volltextzugriff (PDF)

Effects of Type 1 Diabetes on Osteoblasts, Osteocytes, and Osteoclasts

Current osteoporosis reports, 2016-12, Vol.14 (6), p.310-319

2016

Volltextzugriff (PDF)

Canagliflozin, an SGLT2 inhibitor, corrects glycemic dysregulation in TallyHO model of T2D but only partially prevents bone deficits

Bone (New York, N.Y.), 2020-12, Vol.141, p.115625-115625, Article 115625

2020

Volltextzugriff (PDF)

Early developmental changes in IGF-I, IGF-II, IGF binding protein-1, and IGF binding protein-3 concentration in the cerebrospinal fluid of children

Pediatric research, 2005-07, Vol.58 (1), p.89-93

2005

Volltextzugriff (PDF)

Genetic ablation of SGLT2 function in mice impairs tissue mineral density but does not affect fracture resistance of bone

Bone (New York, N.Y.), 2020-04, Vol.133, p.115254-115254, Article 115254

2020

Volltextzugriff (PDF)

Constitutive activation of MEK1 in osteoprogenitors increases strength of bone despite impairing mineralization

Bone (New York, N.Y.), 2020-01, Vol.130, p.115106-115106, Article 115106

2020

Volltextzugriff (PDF)

Regulation of Insulin-Like Growth Factor (IGF)-I Action by Matrix Metalloproteinase-3 Involves Selective Disruption of IGF-I/IGF-Binding Protein-3 Complexes

Endocrinology (Philadelphia), 2004-02, Vol.145 (2), p.620-626

2004

Volltextzugriff (PDF)

1202-P: Glucose Lowering with an SGLT2I Improves Trabecular Bone but Does Not Correct Bone Brittleness in TallyHo Model of T2D

Diabetes (New York, N.Y.), 2019-06, Vol.68 (Supplement_1)

2019

Volltextzugriff (PDF)

Physiological matrix metalloproteinase (MMP) concentrations: comparison of serum and plasma specimens

Clinical chemistry and laboratory medicine, 2006-01, Vol.44 (4), p.503-504

2006

Volltextzugriff (PDF)

Is insulin an anabolic agent in bone? Dissecting the diabetic bone for clues

American journal of physiology: endocrinology and metabolism, 2005-11, Vol.52 (5), p.E735-E745

2005

Volltextzugriff (PDF)

IGFBP-4 degradation by pregnancy-associated plasma protein-A in MC3T3 osteoblasts

Biochemical and biophysical research communications, 2004-12, Vol.325 (3), p.698-706

2004

Volltextzugriff (PDF)

1 – 25 von 27

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(26)
Mit Volltextzugriff
(27)

Publikationsform

Artikel
(27)

Sprache

Englisch
(27)
Japanisch
(6)

Erscheinungsjahr

n.n

Thema

Science & Technology
(22)
Life Sciences & Biomedicine
(21)
Endocrinology & Metabolism
(19)
Animals
(16)
Mice
(11)
Male
(10)
Diabetes
(9)
Humans
(9)
Biological And Medical Sciences
(8)
Female
(7)
Fundamental And Applied Biological Sciences. Psychology
(6)
Insulin
(6)
Medical Sciences
(6)
Cortical Bone
(5)
Diabetes. Impaired Glucose Tolerance
(5)
Endocrine Pancreas. Apud Cells
(5)
Endocrinopathies
(5)
Etiopathogenesis. Screening. Investigations. Target Tissue Resistance
(5)
Orthopedics
(5)
Type 1 Diabetes
(5)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Low bone toughness in the TallyHO model of juvenile type 2 diabetes does not worsen with age

Postnatal loss of the insulin receptor in osteoprogenitor cells does not impart a metabolic phenotype

SGLT2 inhibitor therapy improves blood glucose but does not prevent diabetic bone disease in diabetic DBA/2J male mice

The impact of SGLT2 inhibitors, compared with insulin, on diabetic bone disease in a mouse model of type 1 diabetes

Is insulin an anabolic agent in bone? Dissecting the diabetic bone for clues

Matrix metalloproteinases: their potential role in the pathogenesis of diabetic nephropathy

Microalbuminuria in Type 1 Diabetes Is Associated With Enhanced Excretion of the Endocytic Multiligand Receptors Megalin and Cubilin

Increasing duration of type 1 diabetes perturbs the strength–structure relationship and increases brittleness of bone

Insulin-like growth factor binding protein proteolysis

Pharmacologic Inhibition of Myostatin With a Myostatin Antibody Improves the Skeletal Muscle and Bone Phenotype of Male Insulin‐Deficient Diabetic Mice

Runt-Related Transcription Factor 2 (RUNX2) and RUNX2-Related Osteogenic Genes Are Down-Regulated throughout Osteogenesis in Type 1 Diabetes Mellitus

RASopathies: The musculoskeletal consequences and their etiology and pathogenesis

Osteo-promoting effects of insulin-like growth factor I (IGF-I) in a mouse model of type 1 diabetes

Preserving and restoring bone with continuous insulin infusion therapy in a mouse model of type 1 diabetes

Loss of Insulin Receptor in Osteoprogenitor Cells Impairs Structural Strength of Bone

Effects of Type 1 Diabetes on Osteoblasts, Osteocytes, and Osteoclasts

Canagliflozin, an SGLT2 inhibitor, corrects glycemic dysregulation in TallyHO model of T2D but only partially prevents bone deficits

Early developmental changes in IGF-I, IGF-II, IGF binding protein-1, and IGF binding protein-3 concentration in the cerebrospinal fluid of children

Genetic ablation of SGLT2 function in mice impairs tissue mineral density but does not affect fracture resistance of bone

Constitutive activation of MEK1 in osteoprogenitors increases strength of bone despite impairing mineralization

Regulation of Insulin-Like Growth Factor (IGF)-I Action by Matrix Metalloproteinase-3 Involves Selective Disruption of IGF-I/IGF-Binding Protein-3 Complexes

1202-P: Glucose Lowering with an SGLT2I Improves Trabecular Bone but Does Not Correct Bone Brittleness in TallyHo Model of T2D

Physiological matrix metalloproteinase (MMP) concentrations: comparison of serum and plasma specimens

Is insulin an anabolic agent in bone? Dissecting the diabetic bone for clues

IGFBP-4 degradation by pregnancy-associated plasma protein-A in MC3T3 osteoblasts

Suchergebnisse filtern